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ABSTRACT 
Objective: The present study was designed to formulate and evaluate the orodispersible tablets of lamotrigine after enhancing its solubility. 
Methods: Lamotrigine was made into an inclusion complex with eudragit E 100 my kneading and mass extrusion method and later this mixture is 
compressed into orodispersible tablet using various super disintegrants and co-processed excipients to reduce the disintegration time for providing 
prompt action through rapid drug release. 
Results: Lamotrigine ODTs containing F-melt (F1-3%, F2-5%) dispersed in lesser time of (9±0.11) and (21±0.58) compared to formulations with 
polyplasdone XL-10 and primellose as super disintegrants respectively with F1 showing short wetting time. The water absorption was also was 
found to be more for formulation with 3% F-Melt. 
Conclusion: Lamotrigine orodispersible tablets were prepared by direct compression technique by using 3% and 5% of three super disintegrants 
(f-melt, primellose and polyplasdone XL-10). Disintegration time of F1 (3% f-melt) formulation was found to be least (7 sec). 
Keywords: Tablets of lamotrigine using, Coprocessed excipients 
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INTRODUCTION 
Orodispersible technique is the best way to delivery such kind of active 
pharmaceuticals which are required to elicit action immediately. 
Epilepsy is a neuronal disorder occurring all age groups and is a 
pathophysiological condition which requires immediate treatment [1]. 
Lamotrigine is chemically 3, 5-diamino-6-(2, 3-dichlorophenyl)-as-
triazine, having a molecular formula C9H7N5Cl2, which is supposed to 
be acting by inhibiting voltage gated sodium channels and thus 
reducing the release of glutamate, an excitatory amino acid 
responsible in the initiation and dissemination of a seizure [2]. 
Lamotrigine shows good absorption profile but is poorly soluble in 
water. Thus it is required to formulate the dosage form, which 
modifies the solubility profile thus making it more bioavailable.  
For this reason lamotrigine is complexed with eudragit E 100 by 
mass extrusion method. Then this complex is further blended with 
super disintegrants polyplasdone XL-10 or primellose or 
coprocessed excipient F-Melt and other excipients. Tablets were 
prepared by the direct compression method. Fast melting and taste-
masking provide increased patient compliance. The combination of 
WOWTAB and pharmaburst technologies can help in providing 
faster disintegration as well as can provide better mouth feel [3]. 
WOWTAB fast-dissolving/disintegrating tablet formulation uses a 
combination of low and high mouldability saccharides for rapid 
dissolution and stronger binding property, respectively [4]. 
Pharmaburst technology utilizes co-processed excipient system, 
which works as a quick disintegrating matrix containing 85% of 
sugar polyol D-mannitol,< 10% silicon dioxide,< 10% sorbitol, 5% 
crospovidone produced by cospray drying leading to porous matrix 
enhancing compactibility and also wicking effect making 
disintegration to happen rapidly. 
MATERIALS AND METHODS 
Materials 
Lamotrigine was obtained as a gift sample from Dr. Reddy’s 
Laboratories, (Hyderabad, India), eudragit E-100 by Evonik Degussa 
(Mumbai, India), polyplasdone XL-10 was a gift from ISP 
pharmaceuticals, (Covington, KY,USA), primellose and avicel pH 102 
were gift samples from DFE Pharma (Goch, Germany), F-Melt was 
kindly donated by Fuji Chemical Industry Co., Ltd (Toyama-Pref, 
Japan), lubripharm (sodium stearyl fumarate) was gifted by SPI 
Pharma, (Bengaluru, India), the orange dry flavor was gifted by 
Capricorn Pharma private limited (Hyderabad, India) and ethanol 
and aerosil were procured from SD fine chemicals (Mumbai, India). 
All reagents and solvents were of analytical grade. 
Methods 
Step 1: Preparation of lamotrigine inclusion complex with 
Eudragit E 100 by kneading and mass extrusion method 
Eudragit E100 and lamotrigine were taken in a mortar at a ratio of 
1:1 (eudragit E 100: lamotrigine). To this small quantity of ethanol 
was added with trituration to get slurry like consistency [5]. Then 
slowly lamotrigine (API) was incorporated into the slurry and 
trituration was continued further for 15 min to get a soft mass of 
lamotrigine and eudragit E 100. The soft mass was then transferred 
to a syringe and extruded out and air dried at room temperature for 
24 h, pulverized and passed through sieve no. 60 and was stored in a 
desiccator over fused calcium chloride. 
Step 2: Preparation of lamotrigine orodispersible tablets by 
direct compression method  
Lamotrigine ODTs were prepared by direct compression method. 
Different formulations of lamotrigine orodispersible tablets were 
designed to be prepared by direct compression technique using 
three super disintegrants, (F-Melt, primellose, and polyplasdone XL-
10). Super disintegrants were varied with 2 different concentrations 
(i.e., 3, 5, respectively), keeping all other ingredients constant. 
Formulations designed are assigned with formulation codes shown 
in table 1. 
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Table 1: Formulation codes 
Super disintegrant used Concentration (%) Formulation code 














Marketed formulation - M 
Pure drug - P 
  
Drug-polymer complex, super disintegrants, avicel pH 102, 
aspartame, orange flavor were accurately weighed and passed 
through a 40-mesh screen to get uniform size particles and mixed in 
a glass mortar for 15 min. The obtained blend was lubricated with 
aerosil and glidant (sodium stearyl fumarate) was added and mixing 
was continued for further 5 min. The resultant mixture was directly 
compressed into tablets by using 9 mm round flat-faced punch on a 
rotary tabletting machine. Compression force was kept constant for 
all formulations. Composition of lamotrigine orodispersible tablets is 
shown in table 2 
 
Table 2: Composition of lamotrigine or dispersible tablet 
 Materials (mg)  F1 F2 F3  F4 F5 F6 
Drug-polymer complex  50  50  50  50  50  50  
F-Melt Type C 7.5  12.5  - - - - 
Polyplasdone XL-10  - - - - 7.5  12.5  
Primellose  - - 7.5  12.5  - - 
Aerosil  5  5  5  5  5  5  
Lubripharm  2.5  2.5  2.5  2.5  2.5  2.5  
Aspartame  5  5  5  5  5  5  
Orange Flavor  2.5  2.5  2.5  2.5  2.5  2.5  
Avicel pH 102  177.5  172.5  177.5  172.5 177.5  172.5  
Total weight of tablet (mg) 250  250  250  250  250  250  
 
Evaluation of pre-compression parameters of powder blend 
Angle of repose 
Angle of repose was determined using funnel method. The blend was 
poured through a funnel that can be raised vertically until a maximum 
cone height (h) is obtained. Radius of the heap (r) was measured and 
angle of repose (θ) was calculated using the following formula 
Ө = ℎ/
 
% Compressibility index or carr’s index 
The simplest way for measurement of free flow of powder is 
compressibility, an indication of the ease with which a material can 
be induced to flow is given by compressibility index which was 
determined by the formula 
Carrs index = ρ − ρ/ρ ∗ 100 
Where ρt = tapped density and ρb = bulk density.  
Hausner’s Ratio (H)  
Hausner’s ratio is an indirect index of ease of powder flow. It was 





Where ρt = tapped density and ρb = bulk density  
Evaluation of post compression parameters of lamotrigine 
ODTs 
Different quality control tests were performed for all the ODT 
formulations to check whether these have met the specifications 
given in USP along with other in vitro tests like wetting time and 
water absorption ratio. 
Weight variation test 
20 tablets were randomly selected from each formulation and their 
individual weights and average weight of all 20 tablets was 
calculated by weighing on an electronic balance (Shimadzu, AUX 
220, Shimadzu Corp, Japan) [6]. The mean±SD was noted.  
Thickness 
Randomly 10 tablets were taken from each formulation and their 
thickness was measured using a digital Vernier caliper (Mitutoyo 
Corp, Kawasaki, Japan). Average thickness and standard deviation 
values were calculated. The tablet thickness should be controlled 
within a±5% variation of standard value [7]. 
Hardness 
The tablet hardness of different formulations was measured using 
the Monsanto hardness tester. The tester consists of a barrel 
containing a compressible spring held between two plungers. The 
lower plunger was placed in contact with the tablet, and a zero was 
taken. The upper plunger was then forced against the spring by 
turning a threaded bolt until the tablet fractures. As the spring is 
compressed, a pointer rides along a gauge in the barrel to indicate 
the force. The force of fracture is recorded, and the zero force 
reading is deducted from it. Generally, a minimum hardness of 4 
kg/cm2 is considered acceptable for uncoated tablets. The hardness 
for ODTs should be preferably 1-4 kg/cm2 [8]. 
Friability 
This test was performed using a laboratory friability tester known as 
Roche friabilator. 20 tablets were weighed and placed in a plastic 
chambered friabilator attached to a motor, which revolves at a speed 
of 25 rpm, dropping the tablets from a distance of 6 inches with each 
revolution. The tablets were subjected to 100 revolutions for 4 min. 
After the process, these tablets were de-dusted and reweighed. 
Percentage loss of tablet weight was calculated. Friability values 





Where W1 = Initial weight of 10 tablets and W2 = Final weight of 10 
tablets [9]. 
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Drug content 
3 tablets were randomly selected, weighed and finely powdered and 
the quantity of powder equivalent to one tablet was added to 100 ml 
of 6.8 pH phosphate buffer in a conical flask. A conical flask was then 
placed on a rotary shaker. An aliquot of the solution was centrifuged 
and the supernatant was filtered through a 0.22µ filter. Absorbance 
of the resulted supernatant solution was measured using U. V Visible 
double beam spectrophotometer at a wavelength of 308 nm against 
6.8 pH phosphate buffer as blank. Concentrations and amount of 
drug present in one tablet were calculated with the help of 
calibration curves [10-12]. 
Wetting time 
A piece of tissue paper folded twice was placed in a small petridish 
containing 6 ml of water. Water-soluble dye phenolphthalein was 
added to the petridish. The dye solution was used to identify the 
complete wetting of the tablet surface [13, 14]. A tablet was carefully 
placed on the surface of tissue paper in the petridish at room 
temperature. The time required for water to reach the upper surface of 
the tablets and completely wet them was noted as the wetting time. To 
check for reproducibility, the measurements were carried out in 
triplicates (n=3). The wetting time was recorded using a stopwatch. 
Water absorption ratio (r) 
The weight of the tablet before keeping in the petridish was noted 
(Wb) using shimadzu digital balance. The wetted tablet from the 
petridish was taken and reweighed (Wa`) using the same [15]. The 
Water absorption ratio, R, was determined according to the 





Where Wa= Weight of the tablet after absorption and Wb= Weight of 
the tablet before absorption. 
In vitro dispersion time 
In vitro dispersion time was determined by placing one tablet in a 
beaker containing 10 ml of pH 6.8 phosphate buffer at 37±0.5 °c and 
the time required for complete dispersion was determined. To check 
for reproducibility, the measurements were carried out in triplicates 
(n=3). The dispersion time was recorded using a stopwatch [13]. 
In vitro disintegration time 
A piece of tissue paper folded twice was placed in a small petridish 
containing 6 ml of pH 6.8 phosphate buffer. A tablet was carefully 
placed on the surface of tissue paper in the petridish at room 
temperature. The time required for water to reach the upper surface of 
the tablets and completely wet them and break down into small 
particles was noted as the in vitro disintegration time. To check for 
reproducibility, the measurements were carried out in triplicates 
(n=3). The disintegration time was recorded using a stopwatch [16, 
17]. 
In vitro dissolution studies 
Method 
Dissolution test was carried out by using USP type II apparatus. The 
paddle was rotated at 50 rpm. 6.8 pH phosphate buffer was used as 
dissolution medium (900 ml) and was maintained at 37±1 °C. 
Samples of 5 ml were withdrawn at predetermined intervals (1, 
3,5,10,15,20,25,30,45,60 min), filtered and replaced with 5 ml of 
fresh dissolution medium. The collected samples were suitably 
diluted with dissolution fluid, where ever necessary and were 
analyzed for the drug at 308 nm by using ultra violet double beam 
spectrophotometer. Each dissolution study was performed for three 
times and mean values were taken [18-20]. 
Fourier transform infrared spectroscopy (FTIR) 
FTIR studies were performed on drug, drug-polymer complex. F-
melt, optimized formulation using Shimadzu FTIR (Prestige, India). 
The samples were analyzed between wave numbers 4000 and 400 
cm-1. 
Stability studies  
Moisture uptake studies 
Moisture uptake studies for ODT were conducted to assess the 
stability of the formulation. Ten tablets from each formulation were 
kept in a desiccator over calcium chloride at 37 °C for 24h. The 
tablets were then weighed and exposed to 75% relative humidity, at 
room temperature for two weeks. The relative humidity was 
achieved by was achieved by keeping saturated sodium chloride 
solution at the bottom of the desiccator for 3 d. One tablet as control 
(without super disintegrants) was kept to assess the moisture 
uptake due to other excipients. Tablets were then weighed and the 
percentage increase in weight was recorded [21-24]. 
RESULTS AND DISCUSSION 
Evaluations of precompression parameters of lamotrigine ODTs 
Precompression parameters were measured as per standard 
procedure and the values obtained are as shown in table 3. 
 
Table 3: Evaluation of pre-compression parameters of powder blend 
Formulation Bulk density* 
(g/ml) 
Tapped density* (g/ml) Carr's index* (%) Angle of repose* (θ) Hausner’s 
ratio* 
F 1 0.64±0.03 0.59±0.03 6.02±0.05 25±0.02 0.91±0.02 
F2 0.62±0.01 0.58±0.02 6.08±0.06 26±0.05 0.92±0.07 
F3 0.62±0.08 0.58±0.05 7.50±0.01 28±0.04 0.93±0.03 
F4 0.60±0.03 0.56±0.04 7.45±0.02 29±0.05 0.92±0.05 
F5 0.55±0.05 0.50±0.03 7.21±0.04 27±0.03 0.96±0.06 
F6 0.54±0.02 0.53±0.01 7.53±0.05 29±0.01 0.96±0.06 
 *Results are the mean of 3 observations±SD. 
 
For each formulation blend of drug and excipients were 
prepared and evaluated for various Precompression parameters 
and the bulk density of all formulations was found in the range 
of (0.54±0.020-0.64±0.03) and tapped density was in range of 
(0.50±0.03-0.59±0.03). The Carr’s index and Hausner’s ratio was 
calculated from tapped density and bulk density. The powder 
blend of all six formulations with Hausner’s ration<1.25 and 
Carr’s index<14 indicates excellent flow ability of all powder 
blends. The flow properties for all the powder blends were 
excellent as evidentially proved by the angle of repose values 
obtained, which ranged between (25.02 °–29.05 °) better than 
that of pure drug. 
Evaluations of post-compression parameters of lamotrigine ODTs 
The prepared tablets were characterized for various tests and the 
results were as shown in table 4. 
Weight variation and thickness 
All the formulations were evaluated for uniformity of weight using 
electronic weighing balance and the results are shown in table 4. The 
average tablet weight of all the formulations was found to be 
between (248.4±0.78 to 250.3±0.55). The maximum allowed 
percentage weight variation for tablets weighing 80-250 mg by I. P is 
7.5% and no formulations are exceeding this limit. Thus all the 
formulations were found to comply with the standards given in I. P. 
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Table 4: Evaluation of post-compression parameters of lamotrigine orodispersible tablets 
Formulation Weight variation* Thickness (mm)** Hardness*** Kg/cm2 % Friability*  Drug content*** 
F1 248.4±0.78 3.16±0.08 3.2±0.11 0.33±0.21 102.43±0.5 
F2 250.2±0.63 3.13±0.1 3.1±0.19 0.36±0.03 101.07±0.8 
F3 249.8±0.6 3.14±0.1 3.2±0.15 0.54±0.15 101.75±0.3 
F4 250.3±0.55 3.18±0.08 3.1±0.18 0.59±0.11 101.13±0.7 
F5 249.6±0.52 3.15±0.05 3.1±0.22 0.63±0.19 99.69±0.21 
F6 249.2±0.4 3.14±0.07 3.3±0.13 0.65±0.08 99.94±0.48 
*Results are the mean where n is 20±SD, **Results are the mean where n is 10±SD and ***Results are the mean where n is 3±SD 
 
Hardness 
All the ODT formulations were evaluated for their hardness, using 
Monsanto hardness tester. The average hardness for all the 
formulations was found to be between (3.1±0.18 to 3.3±0.13) 
Kg/cm2 which was found to be acceptable, the hardness for F4 
(3.1±0.18 Kg/cm2) was found to be least and for F6 (3.3±0.13 
Kg/cm2) was found to be the highest of all the formulations. 
Friability 
All the ODT formulations were evaluated for their percentage 
friability using Roche friabilator and the results are shown in table 
8.3. The average percentage friability for all the formulations was 
between (0.33±0.21% to 0.65±0.08 %), which was found to be 
within the limit. 
Drug content  
All the formulations were evaluated for drug content according to 
the procedure described in methodology section and the results 
were shown in table 4. The assay values for all the formulations 
were found to be in the range of (99.69±0.219 to 102.43±0.5). 
According to IP standards the tablets must contain not less than 95% 
and not more than 105% of the stated amount of the drug. Thus, all 
the ODT formulations comply with the standards given in IP. 
In vitro disintegration time  
In vitro disintegration studies showed that ODTs containing F-Melt 
(F1-3%, F2-5%) showed lesser disintegration time of (7±0.78) and 
(13±0.63) compared to formulations with Polyplasdone XL-10 and 
Primellose as super disintegrants respectively. These results 
indicate that increasing the concentration of F-Melt in the tablets 
results in the formation of more cohesive tablets that are less likely 
to break up or dissolve easily in water. These results are further 
confirmed by wetting time in which tablets containing 3% F-Melt 
showed significantly short wetting time (2.16±0.08) compared to 
tablets containing 5% F-Melt (8.13±0.1) short wetting time is 
indicative of the highly porous nature of the tablet matrix. The 
disintegrating time of formulations containing F-Melt was lower 
than those containing Primellose and Polyplasdone XL-10, which 
might be attributed due to its rapid water absorbing nature 
involving both wicking and swelling mechanisms, and delayed 
disintegration time for other super disintegrants due to their 
tendency to gel more than F-Melt. The in vitro disintegration time for 
all formulation was between 7 to 30 seconds as shown in fig. 1. 
Wetting time 
Wetting time corresponds to the time required to wet completely 
when kept motionless on the tissue paper in a petridish. All the ODT 
formulations were evaluated for their wetting time as per the 
procedure described in the methodology section, and the results are 
shown in fig. 2. The average wetting time for all the formulations 
was in the range of (2.16±0.08 to 21.15±0.05) seconds. The 
formulation F1 (3% F-Melt) have shown lowest wetting time of 
(2.16±0.08) seconds and the formulation F5 (3 % Polyplasdone XL-
10) have shown highest wetting time of (21.15±0.05) seconds. It was 
also observed that formula F1 which had the least wetting time also 
had the minimum disintegration time showing a strong correlation 
between disintegration times and wetting time. 
In vitro dispersion time 
Lamotrigine ODTs containing F-Melt (F1-3%, F2-5%) dispersed in 
lesser time of (9±0.11) and (21±0.58) compared to formulations 
with Polyplasdone XL-10 and Primellose as super disintegrants 
respectively. These results are further confirmed by wetting time in 
which tablets containing 3% F-Melt showed significantly short 
wetting time (2.16±0.08) compared to tablets containing 5% F-Melt 
(8.13±0.1). Short wetting time is indicative of the highly porous 
nature of the tablet matrix. The in vitro dispersion time for all 
formulation was found to be in a range of 9 to 120 seconds. 
Water absorption ratio 
All the formulations were evaluated for water absorption ratio and 
the results were as shown in fig. 4. The maximum water absorption 
ratio was shown by formulation F1 (96±0.78). 
  
 
Fig. 1: Comparison of in vitro disintegration time of formulations comprising 3% and 5% of super disintegrants (F-Melt, Primellose and 
Polyplasdone XL-10) and marketed formulation 
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Table 5: Evaluation of other post-compression parameters of lamotrigine or dispersible tablets compared with marketed tablets 
Formulation Disintegration time* 
(sec) 




F1 7±0.78 2.16±0.08 9±0.11 96±0.78 
F2 13±0.63 8.13±0.10 21±0.58 88±0.63 
F3 21±0.6 12.14±0.10 38±0.15 85±0.60 
F4 26±0.55 17.18±0.08 41±0.32 81±0.55 
F5 30.6±0.52 21.15±0.05 48±0.27 79.±0.52 
F6 29.2±0.4 19.14±0.07 45±0.48 81±0.40 
M 30.6±0.51 22.15±0.05 120±0.05 89.±0.05 
*Results are the mean where n is 3±SD 
 
 
Fig. 2: Comparison of wetting time of formulations comprising 3% and 5% of super disintegrants (F-Melt, Primellose and Polyplasdone 
XL-10) and marketed formulation 
 
 
Fig. 3: Comparison of in vitro dispersion time of formulations comprising 3% and 5% of super disintegrants (F-Melt, Primellose and 
Polyplasdone XL-10) and marketed formulation 
 
 
Fig. 4: Comparison of water absorption ratio of formulations comprising 3% and 5% of super disintegrants (F-Melt, Primellose and 
Polyplasdone XL-10) and marketed formulation 
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In vitro drug release 
All the tablets prepared were subjected to in vitro dissolution studies 
in USP type II apparatus. The tablets prepared from three super 
disintegrants (F-Melt, primellose and polyplasdone XL-10) i.e., 
formulations (F1–F6) showed a drug release between (99-102%). 
Among six batches, batch F1 is selected as optimized batch because 
of its lowest disintegration time and highest drug release at 10 min 
when compared to other formulations. A short wetting time and 
highest water absorption ratio with no significant moisture uptake 
formulation F1 with 3% F-Melt was unique of all and considered to 
be optimized formulation as shown in table 6 and fig. 5. 
The % drug release for the optimized formulations F1 prepared by 
3% of super disintegrant (F-Melt) at 10 min was found to be 
100.49±0.05 which is better than marketed formulation and pure 
drug with 57.97524±0.02 and 55.75506±0.91. As lamotrigine 
orodispersible tablets are meant for fast action, especially for 
patients suffering from epileptic seizures need immediate treatment 
when they get seizures these ODTs show fast action and get 
immediate relief. Optimized formulation F1 has less quantity of 
super disintegrant but showed quicker dissolution rate as shown in 
fig. 6. 
Moisture uptake study  
The optimized formulation (F1) lamotrigine orodispersible tablets 
prepared with 3% F-Melt showed no moisture uptake as it is non-
hygroscopic in nature, as shown in table 7. 
  
Table 6: In vitro drug release profile of all six formulations of lamotrigine ODTs 
Time (min) 3%DRF* 5%DRF* 3%DRP* 5%DRP* 3%DRPX*  5%DRPX* 
1 47.17±0.06 43.76±0.01 34.33±0.09 23.33±0.03 12.33±0.09  13.44±0.03 
3 65.90±0.07 62.43±0.03 41.33±0.07 36.37±0.01 26.57±0.15  27.71±0.02 
5 84.42±0.05 73.36±0.08 61.57±0.09 56.97±0.03 34.02±0.29  35.14±0.01 
10 100.20±0.10 87.57±0.04 93.60±0.87 79.81±0.02 54.42±0.10  55.40±0.01 
15 102.18±0.95 100.49±0.05 97.34±0.98 97.12±0.05 73.84±0.25  74.41±0.04 
20 102.65±1.02 101.05±0.02 101.60±1.02 100.03±0.04 87.31±0.34  87.63±0.02 
25 102.43±1.25 101.07±0.06 101.75±0.95 100.11±0.05 99.66±0.45  99.87±0.02 
30 102.40±1.23 101.11±0.05 101.71±0.93 100.99±0.06 99.69±0.17  99.93±0.04 
45 102.34±1.24 101.13±0.01 101.66±0.91 101.08±0.06 99.62±0.23  99.94±0.03 
60 102.31±0.06 101.12±0.02 101.62±1.45 101.05±0.02 99.49±0.23  99.92±0.04 
*Results are the mean where n is 3±SD, DRF= Disintegrant F-melt, DRP= Disintegrant primellose, DRPX = Disintegrant polyplasdone XL 
 
 
Fig. 5: In vitro drug release profile of six formulations of lamotrigine ODTs, DRF= Disintegrant F-melt, DRP= Disintegrant primellose, 
DRPX = Disintegrant polyplasdone XL 
 
 
Fig. 6: Comparison of drug release profile of formulations comprising optimized formulation 3 % of F-Melt (super disintegrant) marketed 
formulation and pure drug 
 
Table 7: Moisture uptake study of (F1) optimized formulations of lamotrigine ODTs 
Formulation Average weight of 10 tablets before 
exposed to moisture (mg) 
Average weight of 10 tablets after 
exposed to moisture (mg) 
% moisture uptake 
F1 248.4±0.78 248.4±0.79 0.004 
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FTIR results 
The FTIR spectra of pure drug, inclusion complex F-Melt (super 
disintegrant) and optimized formulation (F1) are taken for the 
characterization studies.  
As the shifts in the positions of major functional groups of the 
lamotrigine and eudragit E100 are observed in the infrared 
spectrum of inclusion complex, it suggests that there is strong 
physical interaction (peak intensities were smoothened and 
disappeared) between drug and polymer as shown in fig. 7. 
 
 
Fig. 7: FTIR spectrum of pure API and other formulations, drug (I), drug polymer complex (II), F-Melt (III) and optimized formulation F1 (IV) 
 
DISCUSSION 
The flowability of all the powder blends was excellent due to their 
flow enhanced by the presence of aerosil which reduces inter 
particulate friction and moreover the formulation containing F-melt 
has good flow characteristics and good compressibility as it is a 
cospray dried excipient [25]. Compared to other formulations those 
containing F-melt showed better compressibility and also have 
shown better disintegration as the material is porous in nature thus 
making wicking effect increase making the tablet disintegrate faster 
which is also strengthened by the observation that the disintegration 
time and water absorption ratio are inversely proportional [26]. It 
was also observed that formula F1 which had the least wetting time 
also had the minimum disintegration time showing a strong 
correlation between disintegration times and wetting time [27]. The 
dispersion time of formulations (F1) containing F-Melt was lower 
than those containing primellose and polyplasdone XL-10, which 
might be attributed due to its rapid water absorbing nature and 
delayed dispersion time for other super disintegrants due to their 
tendency to gel more than F-melt [28]. Water absorption ratio is 
proportional to dissolution rate profile as higher the water 
absorption ratio faster the dissolution [29]. Optimized formulation 
F1 showed faster dissolution because of its high water absorption as 
well as less disintegration time when compared to marketed product 
[30]. Addition of inorganic silicates along with disintegrants will 
shorten the disintegration time which explains why tablets 
containing F-melt showed rapid disintegration time [31]. 
CONCLUSION  
Lamotrigine orodispersible tablets were prepared by direct 
compression technique by using 3% and 5% of three super 
disintegrants (F-Melt, primellose and polyplasdone XL-10). 
Precompression evaluation results showed that all formulations 
exhibited excellent flow properties compared to pure drug which 
has passable flow properties. Tablets of all six formulations (F1-F6) 
were evaluated for uniformity of weight, thickness, hardness and 
they were found to comply with the I. P standards. % friability was 
found to be less than one for all formulations which indicates that 
the tablets have good mechanical strength, which is a basic 
requirement for any orodispersible tablet. Disintegration time is less 
than 30 seconds for all formulation which clearly indicates that the 
formulated tablets are said to be orodispersible tablets. 
Disintegration time of F1 (3% F-Melt) formulation was found to be 
least (7 seconds). It might be due to its rapid water absorbing nature 
involving both capillary and swelling mechanisms, building up the 
pressure internally leading to the faster disintegration. Correlation 
between water absorption ratio ‘R’ and disintegration time was 
observed and the results demonstrated that there is an inverse 
relationship between them.  
ACKNOWLEDGEMENT 
We thank the management of St. Peter’s Institute of Pharmaceutical 
Sciences, Vidyanagar, Hanamkonda, Warangal, Telangana State for 




All the author has contributed equally and Corresponding author 
guided the work and constructed the manuscript.  
CONFLICT OF INTERESTS 
None 
REFERENCES 
1. Abdelbary A, Elshafeey AH, Zidan G. Comparative effects of 
different cellulosic-based directly compressed orodispersible 
tablets on oral bioavailability of famotidine. Carbohydrate 
Polymers 2009;77:799-806. 
2. Ashwini R, Mangesh R, Rahul R. Formulation design and 
optimization of novel taste masked mouth-dissolving tablets of 
tramadol having adequate mechanical strength. AAPS 
PharmSciTech 2009;10:574-81. 
3. Battu SK, Michael AR, Soumyajit M, Madhusudan Y. 
Formulation and evaluation of rapidly disintegrating 
fenoverine tablets: effect of superdisintegrants. Drug Dev Ind 
Pharm 2007;33:1225-32. 
4. Bhatu PB, Atish M. The technologies used for developing orally 
disintegrating tablets: a review. Acta Pharm 2011;61:117–39. 
5. Poonuru RR, Gonugunta CSR. Spatio temporal release of 
lamotrigine by buoyant gastroretentive drug delivery: 
development and evaluation. Int J Pharm Pharm Sci 
2014;6:604-10. 
6. Poonuru RR, Gonugunta CSR. Bimodal gastroretentive drug 
delivery systems of lamotrigine: formulation and evaluation. 
Indian J Pharm Sci 2014;76:476-82. 
Poonuru et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 6, 28-35  
35 
7. Poonuru RR, Gonugunta CSR. Development of buoyant 
controlled release drug delivery systems of atazanavir 
sulphate: effect of various diluents and lubricants on drug 
release. Pharm Int J Adv Pharm Sci 2014;5:1947-57. 
8. Poonuru RR, Ramya SA, Rohini Ch, Pavan J, Lasya RE, Sasya A, 
et al. Development of sublingual tablets of losartan potassium 
with enhanced permeation through mucosa. J Med Pharm Sci 
2020;1:38-43. 
9. Poonuru RR, Abdul RA, Rohini Ch, Pavan J, Swetha S, Akhila M. 
Formulation and in vivo evaluation of mucoadhesive buccal 
tablet of fluvastatin sodium. Asian J Hosp Pharm 2020;1:35-45. 
10. Poonuru RR. The dark side of clinical trials and remedial 
strategies in India. Asian J Hosp Pharm 2020;1:30-4. 
11. Saurabh A, Balaji O, Amita Priya D, Mohan A, Meena K. Lamotrigine 
induced dress syndrome. Asian J Pharm Clin Res 2017;10:3-4. 
12. Francesco C, Elisa C, Paola M, Susanna B, Chiara G, Luisa M. 
Diclofenac fast-dissolving film: suppression of bitterness by a 
taste-sensing system. Drug Dev Ind Pharm 2011;37:252–9. 
13. Goel H, Arora A, Tiwary AK, Rana V. Development and 
evaluation of mathematical model to predict disintegration 
time of fast disintegrating tablets using powder characteristics. 
Pharm Dev Technol 2011;16:57-64.  
14. Guptha A, Mishra AK, Guptha V, Bansal P, Singh R, Singh AK. 
Recent trends of fast dissolving tablet–an overview of 
formulation technology. Int J Pharm Bio Arch 2010;1:1-10. 
15. James K. Dissolution testing of orally disintegrating tablets. Diss 
Tech 2003;10:6-8. 
16. Jianchen X, Li B, Kang Z. Taste masking microspheres for orally 
disintegrating tablets. Int J Pharm 2008;359:63-9. 
17. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly 
disintegrating tablets manufactured by phase transition of 
sugar alcohols. J Controlled Release 2005;105:16-22. 
18. Morita Y, Tsuhima Y, Yasui M, Termoz R, Ajioka J, Takayam K. 
Evaluation of the disintegration time of rapidly disintegrating 
tablets via a novel method utilizing CCD camera. Chem Pharm 
Bull 2002;50:1181-6. 
19. Nishant V, Vikas R. Preparation and optimization of 
mouth/orally dissolving tablets using a combination of glycine, 
carboxymethyl cellulose and sodium alginate: a comparison 
with superdisintegrants. Pharm Dev Technol 2008;13:233-43. 
20. Okuda Y, Irisawa Y, Okimoto K, Osawa T, Yamashita S. A new 
formulation for orally disintegrating tablets using a suspension 
spray-coating method. Int J Pharm 2009;382:80-7.  
21. Rajan K, Sanjay G. Current status of drug delivery technologies 
and future directions. Pharm Tech 20011;25:1-14. 
22. Rakesh P, Mona P, Prabodh C, Sharma, Dhirender K, Sanju N. 
Orally disintegrating tablets–friendly to pediatrics and 
geriatrics. Arch Pharm Res 2010;2:35-48. 
23. Rosie ML, Susan B, Kieran C. Orally disintegrating tablets: the 
effect of recent FDA guidance on ODT technologies and 
applications. Pharm Technol 2009;5:1-6. 
24. Shirwaikar AA. Fast disintegrating tablets of atenolol by dry 
granulation method. Ind J Pharm Sci 2004;66:422-6. 
25. Mishra DN, Bindal M, Singh SK, Kumar SKV. Spray dried 
excipient base: a novel technique for the formulation of orally 
disintegrating tablets. Chem Pharm Bull 2006;54:99–102. 
26. Mishra DN, Bindal M, Singh SK, Kumar SKV. Spray dried 
excipient base: a novel technique for the formulation of orally 
disintegrating tablets. Chem Pharm Bull 2006;54:99–102. 
27. Mistry M. Application-related properties of a new fast 
dispersible excipient. Pharm Tech Eur 2009;2:24–7. 
28. Gohel MC. A review of co-processed directly compressible 
excipients. J Pharm Pharm Sci 2005;8:76–93. 
29. Satyajith P, Nodagala H, Panchagnula US, Srinivasa RB. 
Formulation and evaluation of orodispersible tablets (odts) of 
diclofenac sodium by using superdisintegrant from natural 
origin. Int J Appl Pharm 2019;11:190-7. 
30. Sireesha P, R Kiranjyothi. Formulation and evaluation of 
antidepressant orodispersible tablets. Int J Curr Pharm Res 
2016;8:52-60. 
31. Dobetti L. Fast-melting tablets: developments and technologies. 
Pharm Tech Eur 2000;12:32–42. 
 
